Overview

Study of Trovax® Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer

Status:
Terminated
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the role of combination therapy with Trovax plus Docetaxel or Docetaxel alone in patients with prostate cancer with a rising prostate specific antigen (PSA).
Phase:
Phase 2
Details
Lead Sponsor:
The Methodist Hospital Research Institute
The Methodist Hospital System
Collaborator:
Oxford BioMedica
Treatments:
Docetaxel
Hormones